Citations

Clear

18 citation(s) found for "Schell, W".

Influenza Vaccine Uptake Among Patients with Inflammatory Bowel Disease: Comparable Outcomes Between Telemedicine and In-Person Care
Almasry, Mazen, Richard, Luke J., Farraye, Francis A, Caldera, Freddy, Caldera, Freddy , Caldera, Freddy , Almasry, Mazen, Schell, Trevor , Farraye, Francis A. , Hayney, Mary S.

Mayo Clinic

Crohn's & Colitis 360 | March 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/crocol/otag022 | PMID 42027412 Get It

Abstract Background Patients with inflammatory bowel disease (IBD) receiving immunosuppressive therapies are at increased risk of vaccine-preventable diseases, including influenza. Despite recommendations for annual influenza vaccination, uptake remains suboptimal. The COVID-19 pandemic prompted a surge in telemedicine (Tele-M) use, raising concerns about its impact on vaccination rates due to reduced in-person interactions. This study aimed to assess the impact of IBD-specific Tele-M on influenza vaccine uptake and identify predictors of vaccination in patients with IBD. Methods This single-center retrospective study evaluated influenza vaccine uptake among adult patients with IBD seen between September 2021 and April 2022. Patients were categorized into two groups: Tele-M only and ≥1 in-person visit. Vaccination status was confirmed using the Wisconsin Immunization Registry. Primary outcome was influenza vaccination frequency by visit type, while secondary outcomes evaluated the impact of Tele-M on other vaccinations and predictors of influenza vaccine uptake. Results Among 547 patients, 53.2% received Tele-M only and 46.8% had ≥1 in-person visit. Influenza vaccine uptake was similar between the Tele-M only and ≥1 in-person visit groups (69.0% vs. 75.1%, respectively, p = 0.11). The uptake of pneumococcal, hepatitis B, and zoster vaccines was also comparable. Predictors of higher influenza vaccine uptake included age ≥65, female sex, receipt of ≥ 3 COVID-19 vaccines, and previous influenza vaccination. Conclusions IBD-specific Tele-M did not adversely affect influenza vaccine uptake among patients with IBD. These findings highlight the importance of ensuring vaccination compliance irrespective of healthcare delivery modes. Collaboration among healthcare providers is crucial to improve vaccination rates in patients with IBD.
Society of Critical Care Medicine Guidelines for the Administration of Neuromuscular Blockade in Adults With Acute Respiratory Distress Syndrome
Erstad, Brian L. , Cobas, Miguel Angel, Qadir, Nida , Alshamsi, Fayez, Sharif, Sameer, Devine, Elizabeth M., Einav, Sharon, Elmer, Jennifer, Fort, Alexander C., Harrod, Christopher G., Lamb, Keith D., Mehta, S., Mitchell, Dannette A., Paruk, Fathima, Sacha, Gretchen, Schell‐Chaple, Hildy , Sinha, Sharmili , Smith, S. Ray , TOPELİ, Arzu, Alshamsi, Fayez , Qadir, Nida , Sharif, Sameer , Devine, Scott , Heavner, Mojdeh S. , Lamb, Keith, Mehta, Sangeeta , Piraino, Thomas , Sacha, Gretchen , Smith, Susan E., Topeli, Arzu , Sarwal, Aarti

Mayo Clinic

Critical Care Medicine | March 3, 2026 | Volume: 54 | Issue: 3 | Pages: 634-643

10.1097/ccm.0000000000007002 | PMID 41773929 Get It

Rationale: Neuromuscular blocking agents (NMBAs) show potential benefits on mortality and other complications of acute respiratory distress syndrome (ARDS) in adult patients. Evidence-based decisions and processes ensure appropriate use of neuromuscular blockade in adult patients with ARDS. Objectives: The objective of these guidelines was to develop evidence-based recommendations for the administration of NMBAs in critically ill adult patients with ARDS. Design: The American College of Critical Care Medicine Board convened a 21-member multidisciplinary panel of experts in critical care medicine, nursing, respiratory therapy, pharmacology, surgery, neurology, and anesthesiology. The panel included two expert methodologists specialized in developing evidence-based recommendations in alignment with the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. Conflict-of-interest policies were strictly followed during all phases of guidelines development including task force selection and voting. Methods: The panel members identified and formulated five Population, Intervention, Comparison, and Outcome questions. We conducted a systematic review for each question to identify the best available evidence, statistically analyzed the evidence, and assessed the certainty of the evidence using the GRADE methodology. We used the GRADE evidence-to-decision framework to formulate the recommendations. Results: The panel generated two conditional recommendations. One recommendation is to use NMBAs in adults with ARDS with Pa o 2 /F io 2 less than 150. For the other recommendations, there was equipoise in the recommendation for and against using titratable vs. fixed-dose NMBA dosing, a monitoring-based strategy for assessing depth of sedation and analgesia in adults with ARDS before initiating or while receiving neuromuscular blockade, and administration of NMBAs for patients who are proned, due to overall lack of evidence in critically ill patients and due to considerations of patient safety and experience concerns. Conclusions: These guidelines provide additional perspectives on the use of NMBA in patients with ARDS, recognizing that institutional and patient-specific considerations must help to guide the decision-making process.
Safety of Rotavirus Vaccination in Infants That Were Exposed to Biologics In Utero: A Systematic Review
Schell, Trevor , Fass, Lucas, Hitchcock, Mary , Saha, Sumona , Caldera, Freddy , Schell, Trevor L , Saha, Sumona , Caldera, Freddy , Farraye, Francis A. , Hayney, Mary S.

Mayo Clinic

Inflammatory Bowel Diseases | September 20, 2024 | Volume: 31 | Issue: 7 | Pages: 1789-1796

10.1093/ibd/izae220 | PMID 39303214 Get It

Abstract Background In infants that were exposed to biologics in utero, gastroenterology societal guidelines have either recommended against administration of the live rotavirus vaccine until 6-12 months of age or until serum biologic levels are undetectable. We performed a systematic review to evaluate the safety of rotavirus vaccination in biologic-exposed infants. Methods EMBASE, PubMed, Scopus, and Cochrane databases were searched from 2006 to 2024 for original data reporting on the safety of rotavirus vaccination in infants that were exposed to anti-tumor necrosis factors (TNFs) (ie, infliximab, adalimumab, golimumab, certolizumab) and non-TNF biologics (ie, vedolizumab, ustekinumab, rizankizumab, mirikizumab) in utero. Results A database search yielded 7185 screening results of which 10 studies met inclusion criteria. There were over 300 instances of rotavirus vaccination in biologic-exposed infants (n = 162 exposed to anti-TNFs, n = 142 exposed to non-TNF biologics). Biologic-exposed infants were not at an increased risk of severe adverse events or adverse events of any severity related to rotavirus vaccination. Conclusions Administration of the live rotavirus vaccine appears to be safe in biologic-exposed infants. As such, with careful examination of the risks and benefits, there may be a role for rotavirus vaccination in this population.
Higher and Sustained Cell-Mediated Immune Responses After 3 Doses of mRNA COVID-19 Vaccine in Patients With Inflammatory Bowel Disease on Anti–Tumor Necrosis Factor Therapy
Caldera, Freddy , Rolak, Stacey , Necela, Brian M. , Cogen, Davitte , Zona, Emily E., Schell, Trevor , Ramirez, Oscar Ramirez , Almasry, Mazen, Chun, Kelly , Knutson, Keith L. , Caldera, Freddy , Schell, Trevor L , Ramirez Ramirez, Oscar , Farraye, Francis A. , Hayney, Mary S. , Knutson, Keith L.

Mayo Clinic

Clinical and Translational Gastroenterology | February 13, 2024 | Volume: 15 | Issue: 4 | Pages: e00688

10.14309/ctg.0000000000000688 | PMID 38349178 Get It

INTRODUCTION: Studies suggest that the generation of durable T-cell immunity following coronavirus disease 2019 (COVID-19) vaccination protects against severe disease. The aim of this study was to measure cell-mediated immune response (CMIR) 1–2 months and 6 months after a third dose of a COVID-19 mRNA vaccine. METHODS: This prospective study (HumoRal and CellULar initial and Sustained immunogenicity in patients with inflammatory bowel disease [IBD]) evaluated CMIR at 28–65 days (t 1 ) after dose 2, 28–65 days (t 2 ) (n = 183) and 6 months (±45 days) (t 3 ) (n = 167) after a third dose of an mRNA COVID-19 vaccine. A small cohort had blood sample available 28–65 days (t 4 ) (n = 55) after a fourth dose. Primary outcomes were CMIR at (t 2 ) and (t 3 ). Secondary outcomes included the effect of immunosuppressing IBD medications on CMIR and response at (t 4 ). RESULTS: All patients had measurable CMIR at all time points. CMIR increased at t 2 compared with that at t 1 (median 1,467 responding cells per million (interquartile range [IQR] 410–5,971) vs 313 (94–960) P < 0.001). There was no significant waning in t 2 vs t 3 or significant boosting at t 4 . Those on anti–tumor necrosis factor monotherapy had a higher CMIR compared with those not on this therapy at t 2 (4,132 [IQR 1,136–8,795] vs 869 [IQR 343–3,221] P < 0.001) and t 3 (2,843 [IQR 596–6,459] vs 654 [IQR 143–2,067] P < 0.001). In univariable analysis, anti–tumor necrosis factor monotherapy was associated with a higher CMIR at t 2 ( P < 0.001) and t 3 ( P < 0.001) and confirmed in a multivariable model ( P < 0.001). DISCUSSION: A third dose of a COVID-19 vaccine boosts CMIR, and the response is sustained in patients with IBD.
Racial, Ethnic, and Geographic Disparities in Immunization Rates Among Patients With Inflammatory Bowel Disease
Beniwal‐Patel, Poonam , Waclawik, Gabrielle, Browning, Keely, Urmat, Aijan, Schell, Trevor , Smith, Ryan C. , Huerta, Antonio, Hipp, Lauren E. , Davé, Sonya , Shah, Neemit , Dillon, Kayla E, Reiter-Schreurs, Katelyn, Russ, Rachel K., Mailig, Miguel, Osman, Fauzia , Weiss, Jennifer , Caldera, Freddy , Caldera, Freddy , Schell, Trevor L , Huerta, Antonio, Dillon, Kayla , Farraye, Francis A. , Hayney, Mary S.

Mayo Clinic

Crohn's & Colitis 360 | December 15, 2023 | Volume: 5 | Issue: 4 | Pages: No page available

10.1093/crocol/otad078 | PMID 38130948 Get It

Abstract Background and Aims Racial and ethnic disparities exist in the treatment of IBD. These disparities exist in adult vaccine uptake among the general population and may extend to patients with IBD. The primary aim of this study was to determine whether racial, ethnic, or geographic disparities existed in influenza vaccine uptake among patients with IBD. Methods We performed a multicenter, retrospective cohort study evaluating adult vaccine uptake among patients with IBD seen at two tertiary referral centers between September 2019 and February 2020. The primary outcome was to determine if racial/ethnic and geographic disparities existed in influenza vaccine uptake for the two prior seasons. Our secondary outcomes were to determine if disparities existed for pneumococcal, zoster, or hepatitis B vaccines. Results Among the 2453 patients who met the inclusion criteria, most identified as non-Hispanic White (89.9%), were on immunosuppressive therapy (74.5%), and received the influenza vaccine in both seasons (56.0%). Older age (prevalence ratio (PR) 0.98; 95% confidence interval (95%CI) 0.98-0.99; P &lt; .001) and non-Hispanic White patients (PR 0.76, 95%CI 0.59–0.98, P &lt; 0.03) were significantly more likely to be immunized. Black patients (PR 1.37; 95%CI 1.18–1.59; P &lt; .001) and those living in underserved geographic areas (PR 1.35; 95%CI 1.17–1.56; P &lt; 0.001) were less likely to be immunized. Racial/ethnic and geographic disparities were identified for pneumococcal, zoster, and hepatitis B vaccine uptake. Conclusions Racial and ethnic vaccination uptake disparities exist among patients with IBD; patients from medically underserved areas are also vulnerable to these disparities Studies identifying patient, provider, and system-level opportunities to address these disparities are needed.
S949 Does Telemedicine Impact Influenza Vaccine Uptake in Patients With Inflammatory Bowel Disease?
Almasry, Mazen, Richard, Luke J., Schell, Trevor , Farraye, Francis A. , Hayney, Mary S. , Caldera, Freddy

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S712-S713

10.14309/01.ajg.0000953436.44183.88 Get It

Additional COVID-19 Booster Doses Increase Anti-spike Serum Antibody Concentrations Among Patients With Inflammatory Bowel Disease
Schell, Trevor , Almasry, Mazen, Caldera, Freddy , Ramirez, Oscar Ramirez , Caldera, Freddy , Schell, Trevor L , Ramirez Ramirez, Oscar , Ramirez, Oscar, Farraye, Francis A. , Hayney, Mary S.

Mayo Clinic

Inflammatory Bowel Diseases | April 18, 2023 | Volume: 29 | Issue: 10 | Pages: e38-e39

10.1093/ibd/izad068 | PMID 37071782 Get It

Catastrophic acute failure of pelvic fixation in adult spinal deformity requiring revision surgery: a multicenter review of incidence, failure mechanisms, and risk factors
Martin, Christopher T. , Holton, Kenneth J. , Elder, Benjamin D. , Fogelson, Jeremy L. , Mikula, Anthony L. , Kleck, Christopher J. , Calabrese, David W., Ou-Yang, David , Lovecchio, Francis , Hu, Serena S. , Wood, Kirkham B. , Harper, R. A. Kemp , Ananthakrishnan, Dheera , Schell, Adam, Lieberman, Isador H. , Kisinde, Stanley , DeWald, Christopher J., Colman, Matthew W. , Phillips, Frank M. , Gelb, Daniel E. , Bruckner, Jacob J. , Ross, Lindsey , Johnson, J. Patrick , Kim, Terrence T. , Anand, Neel , Plummer, Zach, Park, Paul , Oppenlander, Mark E., Polly, David W. , Polly, David , Burger, Evalina L. , Patel, Vikas V. , Kim, Han Jo , Harper, Robert, Michael, Keith W. , Nolte, Michael Thomas , Cheng, Joseph S. , Plummer, Zachary J., Sembrano, Jonathan N. , Jones, Kristen E.

Mayo Clinic

Journal of Neurosurgery: Spine | September 23, 2022 | Volume: 38 | Issue: 1 | Pages: 98-106

10.3171/2022.6.spine211559 | PMID 36057123 Get It

OBJECTIVE There are few prior reports of acute pelvic instrumentation failure in spinal deformity surgery. The objective of this study was to determine if a previously identified mechanism and rate of pelvic fixation failure were present across multiple institutions, and to determine risk factors for these types of failures. METHODS Thirteen academic medical centers performed a retrospective review of 18 months of consecutive adult spinal fusions extending 3 or more levels, which included new pelvic screws at the time of surgery. Acute pelvic fixation failure was defined as occurring within 6 months of the index surgery and requiring surgical revision. RESULTS Failure occurred in 37 (5%) of 779 cases and consisted of either slippage of the rods or displacement of the set screws from the screw tulip head (17 cases), screw shaft fracture (9 cases), screw loosening (9 cases), and/or resultant kyphotic fracture of the sacrum (6 cases). Revision strategies involved new pelvic fixation and/or multiple rod constructs. Six patients (16%) who underwent revision with fewer than 4 rods to the pelvis sustained a second acute failure, but no secondary failures occurred when at least 4 rods were used. In the univariate analysis, the magnitude of surgical correction was higher in the failure cohort (higher preoperative T1-pelvic angle [T1PA], presence of a 3-column osteotomy; p < 0.05). Uncorrected postoperative deformity increased failure risk (pelvic incidence–lumbar lordosis mismatch > 10°, higher postoperative T1PA; p < 0.05). Use of pelvic screws less than 8.5 mm in diameter also increased the likelihood of failure (p < 0.05). In the multivariate analysis, a larger preoperative global deformity as measured by T1PA was associated with failure, male patients were more likely to experience failure than female patients, and there was a strong association with implant manufacturer (p < 0.05). Anterior column support with an L5–S1 interbody fusion was protective against failure (p < 0.05). CONCLUSIONS Acute catastrophic failures involved large-magnitude surgical corrections and likely resulted from high mechanical strain on the pelvic instrumentation. Patients with large corrections may benefit from anterior structural support placed at the most caudal motion segment and multiple rods connecting to more than 2 pelvic fixation points. If failure occurs, salvage with a minimum of 4 rods and 4 pelvic fixation points can be successful.
International Consensus Statement on Obstructive Sleep Apnea
Chang, Jolie L. , Goldberg, Andrew N. , Alzoubaidi, Mohammed , Ashbrook, Liza , Auckley, Dennis , Ayappa, Indu , Bakhtiar, H., Bartley, Bethany L. , Billings, Martha E. , Boon, Maurits , Bosschieter, Pien F. N. , Braverman, Itzhak , Brodie, Kara D. , Caesar, Ray, Cahali, Michel Burihan, Cai, Yi , Cao, Michelle , Capasso, Robson , Caples, Sean M., Chang, Corissa P. , Chang, Katherine W. , Chaudhary, Nilika, Cheong, Crystal , Chowdhuri, Susmita , Cistulli, Peter A. , Claman, David M., Collen, Jacob , Coughlin, Kevin , Creamer, Jennifer , Davis, Eric M. , Dupuy-McCauley, Kara , Durr, Megan L. , Dutt, Mohan, Ali, Mazen El, Elkassabany, Nabil , Epstein, Lawrence J., Fiala, Justin A. , Freedman, Neil, Gill, Kirat, Gillespie, M. Boyd , Golisch, Lea, Gooneratne, Nalaka S., Gottlieb, Daniel J. , Green, Katherine K., Gurubhagavatula, Indira , Hayward, Nathan, Hoffmann, Oliver M. G., Holfinger, Steven , Hsia, Jennifer, Huoh, Kevin C. , Inala, Sanjana , Jobanputra, Aesha M. , Johnson, Andrew P. , Junna, Mithri R. , Kado, Jenna T. , Kaffenberger, Thomas M. , Khan, Meena , Kirsch, Douglas B. , Kominsky, Alan, Kryger, Meir H. , Kushida, Clete A. , Kuzniar, Thomas J., Lim, Diane C , Liu, Stanley Yung‐Chuan , MacKay, Stuart G. , Maurer, Joachim T. , May, Anna M. , Mitchell, Ron B. , Mullins, Anna , Nada, Eman , Naik, Sreelatha , Nokes, Brandon , Olson, Michael D. , Pang, Edward B. , Pang, Kenny P. , Perck, Eli Van de , Piccirillo, Jay F. , Pien, Grace W. , Plawecki, Andrea , Quigg, Mark , Ravesloot, Madeline J. L. , Redline, Susan , Rotenberg, Brian , Ryden, Armand, Sarmiento, Kathleen , Sbeih, Firas , Schell, Amy E., Schotland, Helena , Schwab, Richard J. , Seo, Jiyeon , Shah, Neomi , Shelgikar, Anita V., Shochat, Isaac , Soose, Ryan J. , Steele, Toby O. , Stephens, Erika M. , Stepnowsky, Carl , Thaler, Erica R. , Thapa, Sritika, Vries, Nico de, Weaver, Edward M. , Weir, Ian, Wolfe, Lisa F. , Woodson, B. Tucker , Won, Christine , Xu, Josie , Yalamanchi, Pratyusha , Yaremchuk, Kathleen , Yeghiazarians, Yerem, Yu, Jason L. , Zeidler, Michelle , Rosen, Ilene M. , Alt, Jeremiah A , Mohammed, Alzoubaidi , Ashbrook, Liza , Auckley, Dennis , Ayappa, Indu , Bartley, Bethany L , Braverman, Itzhak , Cahali, Michel B , Cai, Yi , Cheong, Crystal S J , Chowdhuri, Susmita , Cistulli, Peter A , Creamer, Jennifer , Dupuy-McCauley, Kara L , Durr, Megan L , Elkassabany, Nabil M , Fiala, Justin A , Gottlieb, Daniel J , Gulati, Arushi , Holfinger, Steven J , Huntley, Colin , Huyett, Phillip , Inala, Sanjana , Ishman, Stacey L , Jobanputra, Aesha M , Kado, Jenna T , Kezirian, Eric J , Kirsch, Douglas B , Kushida, Clete A , Lam, Derek J , Lettieri, Christopher J , Lin, Hsin-Ching , Magalang, Ulysses J , Malhotra, Atul , Mansukhani, Meghna P , Maurer, Joachim T , May, Anna M , Mitchell, Ron B , Mullins, Anna E , Nada, Eman M , Naik, Sreelatha , Nokes, Brandon T , Pack, Allan I , Pien, Grace W , Piper, Amanda J , Ravesloot, Madeline J L , Redline, Susan , Rotenberg, Brian W , Sarmiento, Kathleen F , Schmickl, Christopher N , Shelgikar, Anita Valanju , Shochat, Isaac , Soose, Ryan J , Steele, Toby O , Stephens, Erika , Strohl, Kingman P , Suurna, Maria V , Vanderveken, Olivier M , Yu, Jason L , Rosen, Ilene M , Alt, Jeremiah A. , Barrera, Jose Enrique , Cabrera‐Muffly, Cristina , Chahine, Lana M. , Hoff, Paul T. , Ishman, Stacey L. , Jella, Tarun K. , Kapur, Vishesh K. , Kezirian, Eric J. , Krystal, Andrew D. , Lam, Derek J. , Malhotra, Atul , Mansukhani, Meghna P. , Mokhlesi, Babak , Pack, Allan I , Patil, Susheel P. , Sutherland, Kate

Mayo Clinic

International Forum of Allergy & Rhinology | September 7, 2022 | Volume: 13 | Issue: 7 | Pages: 1061-1482

10.1002/alr.23079 | PMID 36068685 Get It

ABSTRACT Background Evaluation and interpretation of the literature on obstructive sleep apnea (OSA) allows for consolidation and determination of the key factors important for clinical management of the adult OSA patient. Toward this goal, an international collaborative of multidisciplinary experts in sleep apnea evaluation and treatment have produced the International Consensus statement on Obstructive Sleep Apnea (ICS:OSA). Methods Using previously defined methodology, focal topics in OSA were assigned as literature review (LR), evidence‐based review (EBR), or evidence‐based review with recommendations (EBR‐R) formats. Each topic incorporated the available and relevant evidence which was summarized and graded on study quality. Each topic and section underwent iterative review and the ICS:OSA was created and reviewed by all authors for consensus. Results The ICS:OSA addresses OSA syndrome definitions, pathophysiology, epidemiology, risk factors for disease, screening methods, diagnostic testing types, multiple treatment modalities, and effects of OSA treatment on multiple OSA‐associated comorbidities. Specific focus on outcomes with positive airway pressure (PAP) and surgical treatments were evaluated. Conclusion This review of the literature consolidates the available knowledge and identifies the limitations of the current evidence on OSA. This effort aims to create a resource for OSA evidence‐based practice and identify future research needs. Knowledge gaps and research opportunities include improving the metrics of OSA disease, determining the optimal OSA screening paradigms, developing strategies for PAP adherence and longitudinal care, enhancing selection of PAP alternatives and surgery, understanding health risk outcomes, and translating evidence into individualized approaches to therapy.